Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma

- The optimal clinical use of PARP inhibitors-as treatment or maintenance-is unclear.
- Progression-free survival alone may be insufficient to support use as maintenance.
- Clinicians and patients must consider various factors in each setting.
- Potential clinical benefit must be balanced with symptoms from disease or treatment.
- Patient perceptions, such as quality of life, should be considered in both settings.